期刊
NEUROTHERAPEUTICS
卷 19, 期 6, 页码 1818-1831出版社
SPRINGER
DOI: 10.1007/s13311-022-01256-1
关键词
Oncolytic virus; Virotherapy; Glioblastoma; Immunotherapy
Oncolytic virotherapy is a promising modality that uses engineered viruses to combat tumors through direct oncolysis and immune response stimulation, but clinical outcomes vary. This review summarizes relevant studies, discusses technical aspects, emphasizes practical considerations, and explores potential future directions for maximizing efficacy.
Glioblastoma is the most common primary malignant brain tumor in adults and outcomes remain poor despite the current standard of care multimodal therapy. Oncolytic virotherapy utilizes engineered viruses to exert an anti-tumor effect via both direct oncolysis and stimulation of an immune response within the tumor microenvironment, turning tumors from cold to hot. This has shown promise as a novel therapeutic modality and attempts to circumvent the challenges associated with traditional treatments. Many oncolytic viruses have been investigated in completed and ongoing clinical trials and while safety has been demonstrated, clinical outcomes have been variable, often with only a subgroup of patients showing a significant response. This review summarizes these studies, addresses relevant technical aspects of oncolytic virus administration, and highlights practical considerations to assist providers in appropriately caring for patients treated with oncolytic virotherapy. Additionally, future directions within the field that may help to maximize efficacy of this modality are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据